Novolin N Shortage: What Providers and Prescribers Need to Know in 2026

As of 2026, Novolin N (insulin isophane human, NPH) is not on the FDA's official drug shortage database. However, prescribers and clinical pharmacists are regularly fielding calls from patients who cannot locate it locally. This briefing covers the current availability landscape, clinically appropriate alternatives, switching guidance, and resources you can share with patients.

Current Availability Status

Novolin N is manufactured by Novo Nordisk and is currently in commercial production. The product is available in 100 units/mL U-100 concentration in both 10 mL vials and 3 mL FlexPens. While no national FDA shortage exists, localized stocking issues persist at the retail pharmacy level, particularly at independent pharmacies and smaller chains where NPH insulin demand has declined relative to newer basal analogs.

Importantly, Novolin N is also available over-the-counter without a prescription in most U.S. states, making it accessible through pharmacy counters even for uninsured patients. Despite this, patients often encounter access issues related to stocking patterns, cold chain logistics, and pharmacist awareness rather than actual manufacturing shortfalls.

Patient Population Affected

Patients most affected by Novolin N access challenges typically include:

• Uninsured or underinsured patients who rely on NPH insulin for its low cost and OTC accessibility
• Type 1 and type 2 diabetic patients on long-established NPH-based regimens who have good glycemic control and have not been transitioned to analogs
• Patients in rural or underserved areas with fewer pharmacy options
• Pediatric patients with type 1 diabetes managed on NPH-based basal-bolus regimens

Therapeutic Alternatives and Switching Guidance

When Novolin N is unavailable, the following alternatives can be considered:

1. Humulin N (Insulin NPH, Eli Lilly) — The most direct substitution. Same pharmacological class, similar onset (2–4 hr), peak (4–12 hr), and duration (12–18 hr). Unit-for-unit substitution is reasonable, but individual responses can vary due to minor formulation differences. Increase blood glucose monitoring frequency when switching.

2. Insulin Glargine (Lantus, Basaglar, Toujeo, or biosimilars) — When transitioning from once-daily NPH to glargine: initiate at 80% of the NPH dose. For twice-daily NPH, sum the total daily NPH dose and administer 80% as once-daily glargine. Clinical guidelines (ADA Standards of Care) support this transition. Monitor closely for the first 2 weeks post-switch.

3. Insulin Detemir (Levemir) — For type 1 patients transitioning from NPH, consider detemir 1:1 unit substitution initially, then titrate based on glucose response. May require twice-daily dosing for adequate basal coverage in some patients.

4. Insulin Degludec (Tresiba) — For patients who would benefit from greater dosing flexibility. When switching from NPH to degludec, an 80% dose conversion is recommended. Degludec's ultra-long action (42+ hours) requires patient education on timing flexibility.

Clinical Considerations When Switching Basal Insulin

• Increase SMBG frequency during the transition period (minimum daily fasting and bedtime checks)
• Counsel patients on the elimination of NPH's predictable peak — they may need to adjust snack timing if previously using a snack to blunt the NPH peak
• For patients with renal or hepatic impairment, use extra caution with any insulin transition — hypoglycemia risk is higher in these populations
• Document the switch, rationale, and follow-up plan in the patient record

Cost and Access Resources for Patients

Providers play a key role in helping patients navigate the financial and logistical barriers to insulin access. Key resources include:

• Novo Nordisk My Insulin Rx program: Caps out-of-pocket costs at $35/month for eligible commercially insured and uninsured patients. Phone: 1-888-910-0632.
• NovoCare Patient Assistance Program: Free insulin for qualified patients based on income (generally household income below $40,000/year individual, $60,000/year couple).
• GoodRx and SingleCare: Discount coupons can reduce the cash price of Novolin N from ~$135 to ~$44–$49 per 10 mL vial.
• medfinder for providers: medfinder helps your patients locate Novolin N in stock at nearby pharmacies by calling pharmacies on their behalf and texting results. An excellent resource to share with patients who struggle to locate their insulin.

Monitoring and Follow-Up Recommendations

For patients who need to switch insulin due to access issues, schedule a follow-up within 1–2 weeks of any insulin change. Use CGM data or SMBG logs to evaluate glycemic response. Titrate doses conservatively and involve the patient in the decision-making process to support adherence during the transition.

See also our provider guide on how to help your patients find Novolin N in stock.